DataVXJournal of Nanoparticle ResearchPaper
journal article·2011-04

Introduction: designing nanobiotechnology oversight

Leili Fatehi, Susan M. Wolf, Gurumurthy Ramachandran, Jennifer Kuzma

Journal of Nanoparticle Research· Volume 13· Issue 4
Publisher page
Bibliographic record

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

Nanomaterials

OpenAlex topics: Biotechnology and Related Fields

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (8)

Show source-provided references
1. Center for Drug Evaluation and Research (CDER) (2010) Manual of policies and procedures: reporting format for nanotechnology-related information in CMC review. CDER, Silver Spring
2. Environmental Protection Agency (EPA) (2008) Toxic substances control act inventory status of carbon nanotubes. Federal Register 73:64946
3. Kuzma J, Romanchek J, Kokotovich A (2008) Upstream oversight assessment for agrifood nanotechnology: a case studies approach. Risk Anal 28:1081–109810.1111/j.1539-6924.2008.01086.x ↗
4. National Institute for Occupational Safety and Health (NIOSH) (2009) Approaches to safe nanotechnology: managing the health and safety concerns associated with engineered nanomaterials
5. National Nanotechnology Initiative (NNI) (2010) Supplement to the President’s 2011 Budget. Report prepared by the National Science and Technology Council Committee of Technology, Subcommittee on Nanoscale Science, Engineering, and Technology
6. Paradise J, Tisdale AW, Hall RF, Kokkoli E (2009) Evaluating oversight of human drugs and medical devices: a case Study of the FDA and implications for nanobiotechnology. J Law Med Ethics 37:598–62410.1111/j.1748-720X.2009.00434.x ↗
7. Ramachandran G, Wolf SM, Paradise J, Kuzma J, Hall R, Kokkoli E, Fatehi L (2010) Recommendations for oversight of nanobiotechnology: dynamic oversight for complex and convergent technologies (cite to publication in this volume)10.1007/s11051-011-0233-2 ↗
8. Wolf SM, Ramachandran G, Kuzma J, Paradise J (eds) (2009) Symposium on Developing oversight approaches to nanobiotechnology: the lessons of history. J Law Med Ethics 37:543–78910.1111/j.1748-720X.2009.00430.x ↗